At diagnosis, temporal artery biopsy results and large-vessel involvement of patients with giant cell arteritis may be stronger predictors of mortality than cardiovascular risk factors…
Search results for: cardiovascular risk
SLE Patients May Not Receive Enough Cardiovascular Disease Assessment & Treatment
Systemic lupus erythematosus (SLE) is associated with high rates of cardiovascular disease. However, research has shown that aggressive risk assessment with lipid screenings and treatment with statins may be suboptimal for these patients. A new study compared the rates of screening and treatment between SLE patients, diabetes mellitus patients and the general Medicaid population. The results: Despite having an elevated risk of CVD, SLE patients received less lipid testing and fewer statin prescriptions than other patients…
Patients with Psoriatic Arthritis at Increased Risk for Type 2 Diabetes
New research shows that patients with psoriatic arthritis (PsA) have a greater risk for developing type 2 diabetes than patients with psoriasis alone or the general population. Researchers also found that PsA and psoriasis patients have a similar rate of increased risk for cardiovascular disease…
Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
An exploratory analysis of a canakinumab clinical trial has shown the interleukin 1β inhibitor may significantly reduce patients’ risk for gout flares. During the study, patients using canakinumab experienced this decreased risk, but the treatment did not change serum uric acid levels…
Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease
The early identification of endothelial dysfunction may be useful in clinical practice to prevent SLE patients from developing atherosclerosis and cardiovascular disease. New research evaluated the use of peripheral arterial tonometry in assessing endothelial dysfunction in patients with early SLE and no cardiovascular risk factors or disease. The results: These patients showed a high rate of endothelial dysfunction and vascular stiffness…
Antiphospholipid Syndrome: The Risk of Travel at High Altitudes
Antiphospholipid syndrome (APS) is an autoimmune clotting disorder that may present catastrophically with multiple thromboses over a short period of time. In this article, we examine the case of a woman with undiagnosed APS whose first symptoms presented during a long-haul flight. A review of the literature on thrombosis at high altitudes and during long…
A Comprehensive Review of NSAID Cardiovascular Toxicity
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….
Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App
CHICAGO—As good an option as hydroxychloroquine (HCQ) is for many patients with rheumatic diseases, such as rheumatoid arthritis and especially lupus, safety must be an important consideration, an expert said at this April’s ACR State-of-the-Art Clinical Symposium. The use of the antimalarial has become a controversial subject, with clinicians trying to balance the drug’s disease-modifying…
Alendronate May Provide Cardiovascular Benefits; Plus FDA Approves Subcutaneous Tocilizumab
New research has linked alendronate to reduced cardiovascular death in hip fracture patients…
Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
After an independent review, ongoing clinical trials investigating the safety of fasinumab for treating hip or knee OA will discontinue the use of higher fasinumab doses…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 54
- Next Page »